What is MOPEAD?

Models of Patient Engagement for Alzheimer's disease

Novel Research to improve timely diagnosis of Alzheimer's disease through **citizen participation**.

**3 years**

2.000 participants (65-85 years old)

The project will be conducted in **Germany, Slovenia, Spain, Sweden** and the **Netherlands**.

4 strategies to detect memory complaints at their initial stage and provide timely diagnosis

1 Neuropsychological **online test**.

2 Neuropsychological **test** conducted at a **memory clinic**.

3 Neuropsychological **test** carried out by **general practitioners**.

4 Neuropsychological **test** given to **patients diagnosed with type 2 diabetes**.

Why MOPEAD?

2015 **47**million

2050 **131** million

Alzheimer's disease is the most common form of dementia, accounting for 60-80% of all dementia cases.[1]

Only 40-50% of people living with dementia have received a diagnosis.

An **earlier diagnosis** gives people with Alzheimer's disease and their families **'more time' and the opportunity for intervention, including involvement in Clinical Trials.**[2]

EU
Through European research grant and pooling of expertise, MOPEAD encourages a cultural shift towards **making a timely diagnosis** of Alzheimer's disease at its initial stages.

[1] UN Dept of Economic and Social Affairs: https://esa.un.org/unpd/wpp/DataQuery/
[2] World Alzheimer Report 2016: https://www.alz.co.uk/research/WorldAlzheimerReport2011.pdf

MOPEAD's objectives

Evaluate models of **early identification of Alzheimer's** disease.

Assess the tools and processes **for early Alzheimer's detection.**

Establish archetypes for implementation in similar **communities** elsewhere in Europe.

mopead@kiteinnovation.com
www.mopead.eu

@MopeadEU

imi innovative medicines initiative

efpia